HCI-Baylor College of Medicine PDTC

The HCI-Baylor College of Medicine Patient-derived Xenograft Development and Trials Center
(PDTC) is a multi-institutional Center comprising three well-established research groups: two
from the Huntsman Cancer Institute (HCI) at the University of Utah, and one from Baylor
College of Medicine (BCM).


The HCI-BCM PDTC focuses on breast cancer, with 76 patient-derived xenografts (PDX) lines
immediately available for Supplement proposals. In addition, 15 of these PDX models are
currently available as long-term organoid cultures (PDxO).


Supplement proposals may utilize the HCI-BCM combined collection of PDX or PDxO lines. The
most well-characterized PDX lines would be ideal for these short-term (~1 year) projects, and
are described in the following publications:

  • DeRose, Y.S., et al., Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med, 2011. 17(11): p. 1514-20.

  • Zhang, X., et al., A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res, 2013. 73(15): p. 4885-97.

  • Sikora, M.J., et al., Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res, 2014. 74(5): p. 1463-74.

PDX and PDxO lines are available along with companion data including de-identified clinical
data, histology information, clinical markers, whole exome sequencing, RNA sequencing, RPPA
analysis, and selected drug response information. Additional unpublished lines, and organoid
lines derived from each of the HCI PDX models, are also available for collaborative studies. An
outline of models with confirmed biomarkers that are currently available for supplements is
shown below.

The PDX models from the HCI/BCM Anderson PDTC that are available for supplemental projects can be viewed in the attached spreadsheet.

 

FUNDING

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 1U54CA224076-01.

Funding provided by the NIH to the PDXNet Data Commons and Coordination Center (NCI U24-CA224067), to the PDX Development and Trial Centers (NCI U54-CA224083, NCI U54-CA224070, NCI U54-CA224065, NCI U54-CA224076, NCI U54-CA233223, and NCI U54-CA233306) and to the National Cancer Institute Cancer Genomics Cloud (HHSN261201400008C and HHSN261201500003I).